Please login to the form below

Not currently logged in


This page shows the latest AR101 news and features for those working in and with pharma, biotech and healthcare.

Nestlé is set to acquire Aimmune in deal worth $2.6bn

Nestlé is set to acquire Aimmune in deal worth $2.6bn

Palforzia, previously known as AR101, was approved by the US Food and Drug Administration (FDA) in January for use in children aged four to 17 with a confirmed diagnosis of peanut

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    conditions. 2. AR101 – the first peanut allergy treatment. Potentially deadly allergies to food and other everyday substances are on the rise around the world – and there are currently very few therapies ... Analysts say the market could eventually

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...